May. 20 at 1:17 PM
$IBRX — FDA accepted the sBLA to expand Anktiva into MNBIC papillary, with a PDUFA date set for Jan 6, 2027 (standard review). On the surface, this is a constructive regulatory step for ImmunityBio, but the fine print matters here.
FDA is still flagging concerns around reliance on single-arm trial data in papillary disease, which keeps approval uncertainty on the table. Even the company acknowledged those limitations.
Bigger picture: if this ultimately gets approved on single-arm evidence, it could quietly reset expectations for how similar oncology drugs get evaluated going forward—opening the door for competitors like
$JNJ to push their own expansion strategies faster with Inlexzo.
Positive headline, but far from a clear approval path. Market will likely trade the nuance, not just the headline.
